{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:46Z","timestamp":1791612646598,"version":"4.3.4"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/nrneph.2017.92","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T04:24:08Z","timestamp":1499055848000},"page":"563-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Treatment of membranous nephropathy: time for a paradigm shift"],"prefix":"10.1038","volume":"13","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"BFnrneph201792_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/ndt\/gfp665","volume":"25","author":"EP McQuarrie","year":"2010","unstructured":"McQuarrie, E. P., Mackinnon, B., Stewart, G. A. & Geddes, C. C. Membranous nephropathy remains the commonest primary cause of nephrotic syndrome in a northern European Caucasian population. Nephrol. Dial. Transplant. 25, 1009\u20131010 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR2","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco, P. & Debiec, H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 385, 1983\u20131992 (2015).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1681\/ASN.2015111262","volume":"28","author":"DC Cattran","year":"2017","unstructured":"Cattran, D. C., Kim, E. D., Reich, H., Hladunewich, M. & Kim, S. J. Membranous nephropathy: quantifying remission duration on outcome. J. Am. Soc. Nephrol. 28, 995\u20131003 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR4","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti, P., Perna, A. & Remuzzi, G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63, 2254\u20132261 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0270-9295(03)00050-0","volume":"23","author":"A Schieppati","year":"2003","unstructured":"Schieppati, A., Ruggenenti, P., Perna, A. & Remuzzi, G. Nonimmunosuppressive therapy of membranous nephropathy. Semin. Nephrol. 23, 333\u2013339 (2003).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201792_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0272-6386(04)00868-6","volume":"44","author":"RJ Glassock","year":"2004","unstructured":"Glassock, R. J. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am. J. Kidney Dis. 44, 562\u2013566 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201792_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati, A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 329, 85\u201389 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000185178","volume":"50","author":"S Garattini","year":"1988","unstructured":"Garattini, S., Bertani, T. & Remuzzi, G. Steroids and cytotoxic drugs in the treatment of membranous glomerulopathy. Nephron 50, 263\u2013264 (1988).","journal-title":"Nephron"},{"key":"BFnrneph201792_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMp1114866","volume":"366","author":"R Mirnezami","year":"2012","unstructured":"Mirnezami, R., Nicholson, J. & Darzi, A. Preparing for precision medicine. N. Engl. J. Med. 366, 489\u2013491 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR10","doi-asserted-by":"crossref","unstructured":"KDIGO. KDIGO clinical practice guidelines for glomerulonephritis. Chapter 7: idiopathic membranous nephropathy. Kidney Int. Suppl. 2, 186\u2013197 (2012).","DOI":"10.1038\/kisup.2012.20"},{"key":"BFnrneph201792_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1172\/JCI27699","volume":"116","author":"G Remuzzi","year":"2006","unstructured":"Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288\u2013296 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201792_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0272-6386(00)70190-9","volume":"35","author":"P Ruggenenti","year":"2000","unstructured":"Ruggenenti, P. et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am. J. Kidney Dis. 35, 381\u2013391 (2000).","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl. 1","key":"BFnrneph201792_CR13","first-page":"91","volume":"7","author":"RT Gansevoort","year":"1992","unstructured":"Gansevoort, R. T., Heeg, J. E., Vriesendorp, R., de Zeeuw, D. & de Jong, P. E. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol. Dial. Transplant. 7 (Suppl. 1), 91\u201396 (1992).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/00365591003667351","volume":"44","author":"G Kosmadakis","year":"2010","unstructured":"Kosmadakis, G., Filiopoulos, V., Georgoulias, C., Tentolouris, N. & Michail, S. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. Scand. J. Urol. Nephrol. 44, 251\u2013256 (2010).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"BFnrneph201792_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","volume":"46","author":"PW du Buf-Vereijken","year":"2005","unstructured":"du Buf-Vereijken, P. W., Branten, A. J. & Wetzels, J. F. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46, 1012\u20131029 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201792_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov, S., Wall, C. A., Miller, J. A., Scholey, J. W. & Cattran, D. C. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 66, 1199\u20131205 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0272-6386(12)80483-5","volume":"17","author":"M Praga","year":"1991","unstructured":"Praga, M. et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am. J. Kidney Dis. 17, 330\u2013338 (1991).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201792_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0272-6386(12)80696-2","volume":"20","author":"M Praga","year":"1992","unstructured":"Praga, M. et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am. J. Kidney Dis. 20, 240\u2013248 (1992).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201792_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph3010001","volume":"3","author":"P Cravedi","year":"2010","unstructured":"Cravedi, P. et al. Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work? Pharmaceuticals (Basel) 3, 1\u20139 (2010).","journal-title":"Pharmaceuticals (Basel)"},{"key":"BFnrneph201792_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1046\/j.1523-1755.2002.00535.x","volume":"62","author":"R Pisoni","year":"2002","unstructured":"Pisoni, R. et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int. 62, 1010\u20131019 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","volume":"63","author":"R Campbell","year":"2003","unstructured":"Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094\u20131103 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza, F. C. et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5, 2188\u20132198 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza, F. C. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117\u2013125 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/01.CIR.0000047526.08376.80","volume":"107","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti, P. et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107, 586\u2013592 (2003).","journal-title":"Circulation"},{"key":"BFnrneph201792_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan, K. et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J. Am. Soc. Nephrol. 28, 348\u2013358 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","volume":"357","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601\u20131608 (2001).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000045998","volume":"88","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti, P., Brenner, B. M. & Remuzzi, G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 88, 254\u2013259 (2001).","journal-title":"Nephron"},{"key":"BFnrneph201792_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1681\/ASN.2007090970","volume":"19","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213\u20131224 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0272-6386(04)00809-1","volume":"44","author":"A Perna","year":"2004","unstructured":"Perna, A. et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis. 44, 385\u2013401 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201792_CR30","first-page":"61","volume":"22","author":"AM Davison","year":"1984","unstructured":"Davison, A. M., Cameron, J. S., Kerr, D. N., Ogg, C. S. & Wilkinson, R. W. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin. Nephrol. 22, 61\u201367 (1984).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201792_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2215\/CJN.07570712","volume":"8","author":"Y Chen","year":"2013","unstructured":"Chen, Y. et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin. J. Am. Soc. Nephrol. 8, 787\u2013796 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli, C. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9, 444\u2013450 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744\u2013751 (2013).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR34","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli, C. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48, 1600\u20131604 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM198901053200102","volume":"320","author":"C Ponticelli","year":"1989","unstructured":"Ponticelli, C. et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 320, 8\u201313 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR36","unstructured":"Essential Medicines and Health Products Information Portal. Guideline for good clinical practice. ICH harmonised tripartite guideline. E6(R1). Current step 4 version, dated 10 June 1996. (including the post step 4 corrections). The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). http:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js22154en\/ (1996)."},{"key":"BFnrneph201792_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0970-0218.143018","volume":"39","author":"P Saxena","year":"2014","unstructured":"Saxena, P. & Saxena, R. Clinical trials: changing regulations in India. Indian J. Community Med. 39, 197\u2013202 (2014).","journal-title":"Indian J. Community Med."},{"key":"BFnrneph201792_CR38","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha, V. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18, 1899\u20131904 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR39","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou, M. et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100\u2013105 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrneph201792_CR40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0140-6736(12)62033-9","volume":"381","author":"P Ruggenenti","year":"2013","unstructured":"Ruggenenti, P. & Remuzzi, G. Idiopathic membranous nephropathy: back to the future? Lancet 381, 706\u2013708 (2013).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR41","doi-asserted-by":"publisher","unstructured":"van den Brand, J. et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J. Am. Soc. Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2016091022 (2017).","DOI":"10.1681\/ASN.2016091022"},{"key":"BFnrneph201792_CR42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923\u2013924 (2002).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck, L. H. Jr et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR44","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1681\/ASN.2012060602","volume":"23","author":"GB Appel","year":"2012","unstructured":"Appel, G. B. Rituximab in membranous nephropathy: is it a first-line treatment? J. Am. Soc. Nephrol. 23, 1280\u20131282 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1681\/ASN.2013020185","volume":"25","author":"JA van den Brand","year":"2014","unstructured":"van den Brand, J. A., van Dijk, P. R., Hofstra, J. M. & Wetzels, J. F. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J. Am. Soc. Nephrol. 25, 150\u2013158 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR46","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.08880813","volume":"9","author":"JA van den Brand","year":"2014","unstructured":"van den Brand, J. A., van Dijk, P. R., Hofstra, J. M. & Wetzels, J. F. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1066\u20131073 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","volume":"9","author":"AE van de Logt","year":"2016","unstructured":"van de Logt, A. E., Hofstra, J. M. & Wetzels, J. F. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev. Clin. Pharmacol. 9, 1463\u20131478 (2016).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"BFnrneph201792_CR48","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrneph.2013.125","volume":"9","author":"JM Hofstra","year":"2013","unstructured":"Hofstra, J. M., Fervenza, F. C. & Wetzels, J. F. Treatment of idiopathic membranous nephropathy. Nat. Rev. Nephrol. 9, 443\u2013458 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201792_CR49","first-page":"313","volume":"33","author":"DB Jones","year":"1957","unstructured":"Jones, D. B. Nephrotic glomerulonephritis. Am. J. Pathol. 33, 313\u2013329 (1957).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201792_CR50","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3181\/00379727-100-24736","volume":"100","author":"W Heymann","year":"1959","unstructured":"Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G. & Hunter, J. L. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660\u2013664 (1959).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrneph201792_CR51","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","volume":"79","author":"D Kerjaschki","year":"1982","unstructured":"Kerjaschki, D. & Farquhar, M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA 79, 5557\u20135561 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201792_CR52","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053\u20132060 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR53","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M. et al. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286\u20131291 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR54","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137\u20131143 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR55","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","volume":"364","author":"HC Stanescu","year":"2011","unstructured":"Stanescu, H. C. et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 364, 616\u2013626 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR56","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277\u20132287 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/modpathol.2016.32","volume":"29","author":"CP Larsen","year":"2016","unstructured":"Larsen, C. P., Cossey, L. N. & Beck, L. H. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod. Pathol. 29, 421\u2013426 (2016).","journal-title":"Mod. Pathol."},{"key":"BFnrneph201792_CR58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1681\/ASN.2012080771","volume":"24","author":"J Lv","year":"2013","unstructured":"Lv, J. et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J. Am. Soc. Nephrol. 24, 1323\u20131329 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR59","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck Jr","year":"2011","unstructured":"Beck, L. H. Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543\u20131550 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR60","doi-asserted-by":"publisher","first-page":"e62151","DOI":"10.1371\/journal.pone.0062151","volume":"8","author":"YJ Oh","year":"2013","unstructured":"Oh, Y. J., Yang, S. H., Kim, D. K., Kang, S. W. & Kim, Y. S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS ONE 8, e62151 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneph201792_CR61","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech, A. P., Hofstra, J. M., Brenchley, P. E. & Wetzels, J. F. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1386\u20131392 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR62","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","volume":"25","author":"E Hoxha","year":"2014","unstructured":"Hoxha, E. et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J. Am. Soc. Nephrol. 25, 1357\u20131366 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR63","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2215\/CJN.03850414","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha, E., Harendza, S., Pinnschmidt, H., Panzer, U. & Stahl, R. A. M-Type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1883\u20131890 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR64","doi-asserted-by":"publisher","first-page":"e110681","DOI":"10.1371\/journal.pone.0110681","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha, E., Harendza, S., Pinnschmidt, H., Panzer, U. & Stahl, R. A. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS ONE 9, e110681 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneph201792_CR65","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti, P. et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J. Am. Soc. Nephrol. 26, 2545\u20132558 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR66","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","volume":"23","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1735\u20131743 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000437236","volume":"42","author":"SA Timmermans","year":"2015","unstructured":"Timmermans, S. A., Abdul Hamid, M. A., Cohen Tervaert, J. W., Damoiseaux, J. G. & van Paassen, P. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am. J. Nephrol. 42, 70\u201377 (2015).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201792_CR68","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","volume":"83","author":"D Kanigicherla","year":"2013","unstructured":"Kanigicherla, D. et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 83, 940\u2013948 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR69","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","volume":"15","author":"A Radice","year":"2016","unstructured":"Radice, A. et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun. Rev. 15, 146\u2013154 (2016).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneph201792_CR70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha, E. et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J. Am. Soc. Nephrol. 28, 520\u2013531 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR71","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","volume":"270","author":"P Ancian","year":"1995","unstructured":"Ancian, P., Lambeau, G., Mattei, M. G. & Lazdunski, M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem. 270, 8963\u20138970 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph201792_CR72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2014050502","volume":"26","author":"M Fresquet","year":"2015","unstructured":"Fresquet, M. et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J. Am. Soc. Nephrol. 26, 302\u2013313 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR73","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1681\/ASN.2014111061","volume":"27","author":"B Seitz-Polski","year":"2016","unstructured":"Seitz-Polski, B. et al. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J. Am. Soc. Nephrol. 27, 1517\u20131533 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR74","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/ng1010-814","volume":"42","author":"D van der Woude","year":"2010","unstructured":"van der Woude, D. et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat. Genet. 42, 814\u2013816 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrneph201792_CR75","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1681\/ASN.2007030342","volume":"18","author":"P Shah","year":"2007","unstructured":"Shah, P., Tramontano, A. & Makker, S. P. Intramolecular epitope spreading in Heymann nephritis. J. Am. Soc. Nephrol. 18, 3060\u20133066 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR76","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.2215\/CJN.01730408","volume":"3","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti, P. et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin. J. Am. Soc. Nephrol. 3, 1652\u20131659 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR77","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000368589","volume":"128","author":"P Cravedi","year":"2014","unstructured":"Cravedi, P., Remuzzi, G. & Ruggenenti, P. Rituximab in primary membranous nephropathy: first-line therapy, why not? Nephron Clin. Pract. 128, 261\u2013269 (2014).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph201792_CR78","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S. & Fervenza, F. C. A proposal for a serology-based approach to membranous nephropathy. J. Am. Soc. Nephrol. 28, 421\u2013430 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR79","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","volume":"36","author":"H Debiec","year":"2014","unstructured":"Debiec, H. & Ronco, P. Immunopathogenesis of membranous nephropathy: an update. Semin. Immunopathol. 36, 381\u2013397 (2014).","journal-title":"Semin. Immunopathol."},{"key":"BFnrneph201792_CR80","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","volume":"128","author":"TR Cupps","year":"1982","unstructured":"Cupps, T. R., Edgar, L. C. & Fauci, A. S. Suppression of human B lymphocyte function by cyclophosphamide. J. Immunol. 128, 2453\u20132457 (1982).","journal-title":"J. Immunol."},{"key":"BFnrneph201792_CR81","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz, M. D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 6, 859\u2013866 (2006).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR82","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","volume":"14","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 14, 1851\u20131857 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR83","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.05231008","volume":"4","author":"AS Bomback","year":"2009","unstructured":"Bomback, A. S. et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 4, 734\u2013744 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR84","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro, L. D. et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10, 655\u2013661 (1999).","journal-title":"Ann. Oncol."},{"key":"BFnrneph201792_CR85","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825\u20132833 (1998).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201792_CR86","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416\u20131425 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR87","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.142.10.3406","volume":"142","author":"SP Makker","year":"1989","unstructured":"Makker, S. P. & Kanalas, J. J. Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J. Immunol. 142, 3406\u20133410 (1989).","journal-title":"J. Immunol."},{"key":"BFnrneph201792_CR88","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000327611","volume":"33","author":"P Cravedi","year":"2011","unstructured":"Cravedi, P. et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am. J. Nephrol. 33, 461\u2013468 (2011).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201792_CR89","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra, A. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 4, 1083\u20131088 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR90","first-page":"2179","volume":"76","author":"J Bariety","year":"1968","unstructured":"Bariety, J., Samarcq, P., Lagrue, G., Fritel, D. & Milliez, P. Recovery of normal ultrastructure in 2 cases of primary glomerulonephritis with diffuse extra-membranous deposits [French]. Presse Med. 76, 2179\u20132182 (1968).","journal-title":"Presse Med."},{"key":"BFnrneph201792_CR91","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000179748","volume":"6","author":"M Forland","year":"1969","unstructured":"Forland, M. & Spargo, B. H. Clinicopathological correlations in idiopathic nephrotic syndrome with membranous nephropathy. Nephron 6, 498\u2013525 (1969).","journal-title":"Nephron"},{"key":"BFnrneph201792_CR92","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1620\/tjem.120.177","volume":"120","author":"G Osawa","year":"1976","unstructured":"Osawa, G., Kinoshita, Y., Morita, T., Soda, T. & Wada, J. Resolution of diffuse membranous changes with remission of nephrotic syndrome. Tohoku J. Exp. Med. 120, 177\u2013190 (1976).","journal-title":"Tohoku J. Exp. Med."},{"key":"BFnrneph201792_CR93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","volume":"7","author":"S Ambalavanan","year":"1996","unstructured":"Ambalavanan, S., Fauvel, J. P., Sibley, R. K. & Myers, B. D. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 7, 290\u2013298 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR94","doi-asserted-by":"publisher","unstructured":"Marasa, M., Cravedi, P., Ruggiero, B. & Ruggenenti, P. Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. BMJ Case Rep. http:\/\/dx.doi.org\/10.1136\/bcr-2014-205507 (2014).","DOI":"10.1136\/bcr-2014-205507"},{"key":"BFnrneph201792_CR95","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960\u2013968 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph201792_CR96","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph201792_CR97","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph201792_CR98","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR99","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR100","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834\u20134840 (2009).","journal-title":"Blood"},{"key":"BFnrneph201792_CR101","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60, 3761\u20133765 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph201792_CR102","first-page":"S62","volume":"31","author":"G Pugnet","year":"2013","unstructured":"Pugnet, G. et al. Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature. Clin. Exp. Rheumatol. 31, S62\u201364 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrneph201792_CR103","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","volume":"28","author":"AL Sellier-Leclerc","year":"2013","unstructured":"Sellier-Leclerc, A. L., Belli, E., Guerin, V., Dorfmuller, P. & Deschenes, G. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr. Nephrol. 28, 1875\u20131879 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201792_CR104","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/jmv.23339","volume":"84","author":"S Delbue","year":"2012","unstructured":"Delbue, S. et al. Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. J. Med. Virol. 84, 1464\u20131470 (2012).","journal-title":"J. Med. Virol."},{"key":"BFnrneph201792_CR105","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384, 1273\u20131281 (2014).","journal-title":"Lancet"},{"key":"BFnrneph201792_CR106","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti, P. et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 25, 850\u2013863 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR107","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche, J. C. Rituximab-associated infections. Semin. Hematol. 47, 187\u2013198 (2010).","journal-title":"Semin. Hematol."},{"key":"BFnrneph201792_CR108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1741-7015-9-36","volume":"9","author":"S Lanini","year":"2011","unstructured":"Lanini, S. et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 9, 36 (2011).","journal-title":"BMC Med."},{"key":"BFnrneph201792_CR109","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan, C. S. & Koralnik, I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9, 425\u2013437 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrneph201792_CR110","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven, R. F., Fleischmann, R. M., Furst, D. E., Lacey, S. & Lehane, P. B. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J. Rheumatol. 42, 1761\u20131766 (2015).","journal-title":"J. Rheumatol."},{"key":"BFnrneph201792_CR111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106\u2013130 (2006).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrneph201792_CR112","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrneph.2014.37","volume":"10","author":"J Feehally","year":"2014","unstructured":"Feehally, J. Targeted therapies: is there a role for rituximab in nephrotic syndrome? Nat. Rev. Nephrol. 10, 245\u2013247 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201792_CR113","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","volume":"17","author":"E Tavazzi","year":"2011","unstructured":"Tavazzi, E., Ferrante, P. & Khalili, K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 17, 1776\u20131780 (2011).","journal-title":"Clin. Microbiol. Infect."},{"key":"BFnrneph201792_CR114","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford, D. B. et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68, 1156\u20131164 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneph201792_CR115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12208","volume":"92","author":"GP Kaufman","year":"2014","unstructured":"Kaufman, G. P. et al. Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT). Eur. J. Haematol. 92, 83\u201387 (2014).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201792_CR116","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpneph1007","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti, P., Cravedi, P. & Remuzzi, G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat. Clin. Pract. Nephrol. 5, 76\u201377 (2009).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph201792_CR117","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2146\/ajhp090636","volume":"68","author":"S Gabardi","year":"2011","unstructured":"Gabardi, S., Martin, S. T., Roberts, K. L. & Grafals, M. Induction immunosuppressive therapies in renal transplantation. Am. J. Health Syst. Pharm. 68, 211\u2013218 (2011).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"BFnrneph201792_CR118","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","volume":"24","author":"R Pepper","year":"2009","unstructured":"Pepper, R. et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol. Dial. Transplant. 24, 3717\u20133723 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR119","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2215\/CJN.01180307","volume":"2","author":"P Cravedi","year":"2007","unstructured":"Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C. & Remuzzi, G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2, 932\u2013937 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR120","unstructured":"Agenzia Italiana del Farmaco [Italian]. Gazzetta Ufficiale http:\/\/95.110.157.84\/gazzettaufficiale.biz\/atti\/2012\/20120013\/12A00419.htm (2011)."},{"key":"BFnrneph201792_CR121","unstructured":"Medindia. Drug \u201ccyclophosphamide\u201d price list. Medindia http:\/\/www.medindia.net\/drug-price\/cyclophosphamide.htm (updated 2 Feb 2017)."},{"key":"BFnrneph201792_CR122","unstructured":"ASST-PG23. Dialysis costs http:\/\/www.asst-pg23.it\/component\/trasparenza\/12 (2017)."},{"key":"BFnrneph201792_CR123","unstructured":"Goodrx. Tacrolimus https:\/\/www.goodrx.com\/tacrolimus (2017)."},{"key":"BFnrneph201792_CR124","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59, 1484\u20131490 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR125","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga, M., Barrio, V., Juarez, G. F. & Luno, J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924\u2013930 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph201792_CR126","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1440-1797.2010.01301.x","volume":"15","author":"P Kalliakmani","year":"2010","unstructured":"Kalliakmani, P., Koutroulia, E., Sotsiou, F., Vlachojannis, J. G. & Goumenos, D. S. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology (Carlton) 15, 762\u2013767 (2010).","journal-title":"Nephrology (Carlton)"},{"key":"BFnrneph201792_CR127","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000450659","volume":"135","author":"P Cravedi","year":"2017","unstructured":"Cravedi, P. Rituximab in membranous nephropathy: not all studies are created equal. Nephron 135, 46\u201350 (2017).","journal-title":"Nephron"},{"key":"BFnrneph201792_CR128","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl, C. et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann. Rheum. Dis. 70, 1415\u20131421 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph201792_CR129","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03018535 (2017)."},{"key":"BFnrneph201792_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01180036 (2017)."},{"key":"BFnrneph201792_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01955187 (2016)."},{"key":"BFnrneph201792_CR132","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000430849","volume":"130","author":"FC Fervenza","year":"2015","unstructured":"Fervenza, F. C. et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron 130, 159\u2013168 (2015).","journal-title":"Nephron"},{"key":"BFnrneph201792_CR133","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ckj\/sfv075","volume":"8","author":"J Rojas-Rivera","year":"2015","unstructured":"Rojas-Rivera, J. et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary membranous nephropathy: the STARMEN study. Clin. Kidney J. 8, 503\u2013510 (2015).","journal-title":"Clin. Kidney J."},{"key":"BFnrneph201792_CR134","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/ndt\/gfq223","volume":"25","author":"G Moroni","year":"2010","unstructured":"Moroni, G. et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). Nephrol. Dial. Transplant. 25, 3408\u20133415 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR135","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","volume":"8","author":"TS Dabade","year":"2008","unstructured":"Dabade, T. S., Grande, J. P., Norby, S. M., Fervenza, F. C. & Cosio, F. G. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am. J. Transplant. 8, 1318\u20131322 (2008).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR136","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/j.1600-6143.2009.02851.x","volume":"9","author":"ZM El-Zoghby","year":"2009","unstructured":"El-Zoghby, Z. M. et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am. J. Transplant. 9, 2800\u20132807 (2009).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR137","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/oxfordjournals.ndt.a027468","volume":"11","author":"R Marcen","year":"1996","unstructured":"Marcen, R. et al. Membranous nephropathy: recurrence after kidney transplantation. Nephrol. Dial. Transplant. 11, 1129\u20131133 (1996).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR138","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0270-9295(03)00057-3","volume":"23","author":"RD Poduval","year":"2003","unstructured":"Poduval, R. D., Josephson, M. A. & Javaid, B. Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin. Nephrol. 23, 392\u2013399 (2003).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201792_CR139","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1600-6143.2011.03903.x","volume":"12","author":"EF Rodriguez","year":"2012","unstructured":"Rodriguez, E. F. et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am. J. Transplant. 12, 1029\u20131038 (2012).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR140","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","volume":"100","author":"A Grupper","year":"2016","unstructured":"Grupper, A. et al. Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications. Transplantation 100, 2710\u20132716 (2016).","journal-title":"Transplantation"},{"key":"BFnrneph201792_CR141","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/ajt.13133","volume":"15","author":"A Kattah","year":"2015","unstructured":"Kattah, A. et al. Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am. J. Transplant. 15, 1349\u20131359 (2015).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR142","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1097\/TP.0000000000000630","volume":"99","author":"LF Quintana","year":"2015","unstructured":"Quintana, L. F. et al. Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy. Transplantation 99, 1709\u20131714 (2015).","journal-title":"Transplantation"},{"key":"BFnrneph201792_CR143","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","volume":"9","author":"ZM El-Zoghby","year":"2009","unstructured":"El-Zoghby, Z. M. et al. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9, 527\u2013535 (2009).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR144","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellares","year":"2012","unstructured":"Sellares, J. et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am. J. Transplant. 12, 388\u2013399 (2012).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR145","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00467-016-3498-y","volume":"32","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli, M. et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr. Nephrol. 32, 181\u2013184 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201792_CR146","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12, 232\u2013240 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201792_CR147","first-page":"350","volume":"15","author":"A Barbari","year":"2017","unstructured":"Barbari, A. et al. Bortezomib as a novel approach to early recurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy. Exp. Clin. Transplant. 15, 350\u2013354 (2017).","journal-title":"Exp. Clin. Transplant."},{"key":"BFnrneph201792_CR148","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe, F. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170\u2013178 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrneph201792_CR149","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1349-7006.2009.01392.x","volume":"101","author":"S Uchiyama","year":"2010","unstructured":"Uchiyama, S. et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci. 101, 201\u2013209 (2010).","journal-title":"Cancer Sci."},{"key":"BFnrneph201792_CR150","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder, T. F. & Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15, 450\u2013454 (1994).","journal-title":"Immunol. Today"},{"key":"BFnrneph201792_CR151","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/14737140.3.6.767","volume":"3","author":"AJ Grillo-Lopez","year":"2003","unstructured":"Grillo-Lopez, A. J. Rituximab (Rituxan\/MabThera): the first decade (1993\u20132003). Expert Rev. Anticancer Ther. 3, 767\u2013779 (2003).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrneph201792_CR152","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ncpneph0133","volume":"2","author":"AD Salama","year":"2006","unstructured":"Salama, A. D. & Pusey, C. D. Drug insight: rituximab in renal disease and transplantation. Nat. Clin. Pract. Nephrol. 2, 221\u2013230 (2006).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph201792_CR153","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/14712598.2012.735655","volume":"13","author":"P Jain","year":"2013","unstructured":"Jain, P. & O'Brien, S. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin. Biol. Ther. 13, 169\u2013182 (2013).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrneph201792_CR154","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"35","author":"GW van Imhoff","year":"2016","unstructured":"van Imhoff, G. W. et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J. Clin. Oncol. 35, 544\u2013551 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201792_CR155","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang, S., Mukhi, N., Wang, K. & Liu, D. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5, 64 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"BFnrneph201792_CR156","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak, T. & Robak, E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25, 13\u201325 (2011).","journal-title":"BioDrugs"},{"key":"BFnrneph201792_CR157","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","volume":"118","author":"WG Wierda","year":"2011","unstructured":"Wierda, W. G. et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118, 5126\u20135129 (2011).","journal-title":"Blood"},{"key":"BFnrneph201792_CR158","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1136\/ard.2011.151522","volume":"70","author":"PC Taylor","year":"2011","unstructured":"Taylor, P. C. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119\u20132125 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph201792_CR159","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu, B. Ofatumumab for rituximab-resistant nephrotic syndrome. N. Engl. J. Med. 370, 1268\u20131270 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201792_CR160","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0976-500X.155482","volume":"6","author":"M Frieri","year":"2015","unstructured":"Frieri, M., Heuser, W. & Bliss, J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis. J. Pharmacol. Pharmacother. 6, 71\u201376 (2015).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"BFnrneph201792_CR161","doi-asserted-by":"publisher","first-page":"iii32","DOI":"10.1093\/ndt\/gfv149.03","volume":"30","author":"L Willcocks","year":"2015","unstructured":"Willcocks, L. et al. Effect of belimumab on proteinuria and anti-PLA2R autoantibody in idiopathic membranous nephropathy \u2014 6 months data. Nephrol. Dial. Transplant. 30, iii32\u2013iii33 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201792_CR162","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817\u2013826 (2005).","journal-title":"J. Immunol."},{"key":"BFnrneph201792_CR163","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1681\/ASN.2015101170","volume":"27","author":"H Debiec","year":"2016","unstructured":"Debiec, H. & Ronco, P. Immune response against autoantigen PLA2R is not gambling: implications for pathophysiology, prognosis, and therapy. J. Am. Soc. Nephrol. 27, 1275\u20131277 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR164","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"BFnrneph201792_CR165","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","volume":"125","author":"HE Mei","year":"2015","unstructured":"Mei, H. E. et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 125, 1739\u20131748 (2015).","journal-title":"Blood"},{"key":"BFnrneph201792_CR166","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk, N. W. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95\u2013112 (2016).","journal-title":"Immunol. Rev."},{"key":"BFnrneph201792_CR167","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister, S. et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783\u20131792 (2007).","journal-title":"Cancer Res."},{"key":"BFnrneph201792_CR168","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1681\/ASN.2010010034","volume":"22","author":"J Bontscho","year":"2011","unstructured":"Bontscho, J. et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J. Am. Soc. Nephrol. 22, 336\u2013348 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201792_CR169","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748\u2013755 (2008).","journal-title":"Nat. Med."},{"key":"BFnrneph201792_CR170","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474\u20131478 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph201792_CR171","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1136\/annrheumdis-2015-207947","volume":"75","author":"P Novikov","year":"2016","unstructured":"Novikov, P., Moiseev, S., Bulanov, N. & Shchegoleva, E. Bortezomib in refractory ANCA-associated vasculitis: a new option? Ann. Rheum. Dis. 75, e9 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph201792_CR172","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1089\/ars.2014.5892","volume":"21","author":"NS Ejaz","year":"2014","unstructured":"Ejaz, N. S. et al. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid. Redox Signal. 21, 2401\u20132418 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph201792_CR173","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","volume":"27","author":"C Hartono","year":"2014","unstructured":"Hartono, C., Chung, M., Kuo, S. F., Seshan, S. V. & Muthukumar, T. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J. Nephrol. 27, 103\u2013106 (2014).","journal-title":"J. Nephrol."},{"key":"BFnrneph201792_CR174","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/ajt.12514","volume":"13","author":"I Popow","year":"2013","unstructured":"Popow, I. et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am. J. Transplant. 13, 3103\u20133113 (2013).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201792_CR175","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander, T. et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113, 214\u2013223 (2009).","journal-title":"Blood"},{"key":"BFnrneph201792_CR176","unstructured":"Evaluate. Alexion reports presentation of membranous nephritis clinical trials. http:\/\/www.evaluategroup.com\/Universal\/View.aspx?type=Story&id=33783 (2002)."},{"key":"BFnrneph201792_CR177","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","volume":"33","author":"H Ma","year":"2013","unstructured":"Ma, H., Sandor, D. G. & Beck, L. H. Jr. The role of complement in membranous nephropathy. Semin. Nephrol. 33, 531\u2013542 (2013).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201792_CR178","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.semnephrol.2013.08.009","volume":"33","author":"T Takano","year":"2013","unstructured":"Takano, T., Elimam, H. & Cybulsky, A. V. Complement-mediated cellular injury. Semin. Nephrol. 33, 586\u2013601 (2013).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201792_CR179","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/ki.1997.127","volume":"51","author":"DC Cattran","year":"1997","unstructured":"Cattran, D. C. et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 51, 901\u2013907 (1997).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.92","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneph.2017.92","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T07:59:54Z","timestamp":1692863994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":179,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFnrneph201792"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2017.92","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]},"assertion":[{"value":"3 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.C.F. has received unrestricted research grants from Genentech\/Roche, the maker of rituximab. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}